Speaker: Lianne McLean, Fluidigm

Immuno-Oncology (IO) therapies aim to activate or “lift the brakes” off our immune system, making it able to recognise cancer cells and destroy them. It has advanced rapidly with the introduction of immune checkpoint inhibition and effective adoptive T-cell therapies. With increased accessibility to a large number of samples, including FFPE tissues, it becomes apparent that a cost-effective, high-throughput solution is necessary. Fluidigm has recently launched the Advanta IO Gene Expression Panel on the Biomark HD system for studying checkpoint inhibitors. The panel contains genes related to tumor and immune cell biology, and can be used for translational research to develop gene expression signatures that can predict therapeutic response. The speaker will also be sharing with you the development and validation of this qPCR panel. Besides the Advanta IO Panel, you will also learn from this talk the menu in development for NGS library preparation panels and mass cytometry-based immune-monitoring panels that can help you with your research objectives.